董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joan Chypyha | 女 | Director | 59 | 7.34万美元 | 1.39 | 2025-12-12 |
| Charles Olson | 男 | Director | 68 | 6.59万美元 | 1.39 | 2025-12-12 |
| Sean MacDonald | 男 | Director | 49 | 7.47万美元 | 3.38 | 2025-12-12 |
| Carlo Sistilli | 男 | Chairman of the Board | 69 | 10.47万美元 | 4.27 | 2025-12-12 |
| Pardeep Nijhawan | 男 | Director, Chief Executive Officer and Corporate Secretary | 55 | 100.68万美元 | 205.27 | 2025-12-12 |
| Patrick Marshall | 男 | Director | 54 | 7.04万美元 | 5.60 | 2025-12-12 |
| David Liu | 男 | Director | 40 | 3.60万美元 | 0.55 | 2025-12-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Brooks | 男 | President | 47 | 86.19万美元 | 20.55 | 2025-12-12 |
| Pardeep Nijhawan | 男 | Director, Chief Executive Officer and Corporate Secretary | 55 | 100.68万美元 | 205.27 | 2025-12-12 |
| Peter Weiler | 男 | Chief Financial Officer | 56 | 26.47万美元 | 2.17 | 2025-12-12 |
董事简历
中英对照 | 中文 | 英文- Joan Chypyha
-
Joan Chypyha，此前，她曾是Rhei Pharmaceuticals Ltd.的首席开发官；Barrier Therapeutics Inc.的公司发展副总裁；Barrier Therapeutics Canada Inc.的总经理； Alto Pharmaceuticals Ltd.的创会死人。她也在Hoffman-La Roche任职16年并不断被提拔，包括也为透析和部分肠外营养部门主管和皮肤医学的业务部门主管。担任该职位时，她负责代表青春痘特效药等品牌专业销售人员的管理。她获得University of Toronto的学士学位和Queen’s University的工商管理硕士学位。
Joan Chypyha has more than 30 years of experience in the pharmaceutical indtry including executive and operational positions in biness development, sales and marketing, and general management. She is the President of Alto Pharmaceuticals, Ltd., a specialty pharmaceutical company foced on dermatology, women's health and elder care, which she founded in 2009. Alto is also a major shareholder in Pepper and Pink Inc., a manufacturer of brand and private label personal care products for major retailers in Canada. From July 2015 to June 2017, she was the President of Cipher Pharmaceuticals, Inc., having previoly served as Vice President of Marketing and Sales. Ms. Chypyha's professional career also includes executive positions at Rhei Pharmaceuticals Ltd. and Barrier Therapeutics Canada, Inc., following sixteen years at Hoffman La Roche, where she held progressively senior positions. Since February 2018, she has served as a director and a member of the audit committee of Ovation Science Inc., a research and development company that develops topical and transdermal consumer products. She is a past advisory board member of Up Cannabis Inc (from Augt 2017 to January 2019). Ms. Chypyha currently served as the President of the Canadian Dermatology Indtry Association, from 2015 to 2023, and is a Co Chair of DiTiDE (Dermatology Indtry Taskforce on Incliveness, Diversity & Equity), a group she co founded in 2020. She has also previoly served on boards of other non profits and biness organizations, including the Canadian Healthcare Licensing Association. Ms. Chypyha earned her Bachelor's Degree from the University of Toronto and a Master's Degree in Biness Administration from Queen's University. - Joan Chypyha，此前，她曾是Rhei Pharmaceuticals Ltd.的首席开发官；Barrier Therapeutics Inc.的公司发展副总裁；Barrier Therapeutics Canada Inc.的总经理； Alto Pharmaceuticals Ltd.的创会死人。她也在Hoffman-La Roche任职16年并不断被提拔，包括也为透析和部分肠外营养部门主管和皮肤医学的业务部门主管。担任该职位时，她负责代表青春痘特效药等品牌专业销售人员的管理。她获得University of Toronto的学士学位和Queen’s University的工商管理硕士学位。
- Joan Chypyha has more than 30 years of experience in the pharmaceutical indtry including executive and operational positions in biness development, sales and marketing, and general management. She is the President of Alto Pharmaceuticals, Ltd., a specialty pharmaceutical company foced on dermatology, women's health and elder care, which she founded in 2009. Alto is also a major shareholder in Pepper and Pink Inc., a manufacturer of brand and private label personal care products for major retailers in Canada. From July 2015 to June 2017, she was the President of Cipher Pharmaceuticals, Inc., having previoly served as Vice President of Marketing and Sales. Ms. Chypyha's professional career also includes executive positions at Rhei Pharmaceuticals Ltd. and Barrier Therapeutics Canada, Inc., following sixteen years at Hoffman La Roche, where she held progressively senior positions. Since February 2018, she has served as a director and a member of the audit committee of Ovation Science Inc., a research and development company that develops topical and transdermal consumer products. She is a past advisory board member of Up Cannabis Inc (from Augt 2017 to January 2019). Ms. Chypyha currently served as the President of the Canadian Dermatology Indtry Association, from 2015 to 2023, and is a Co Chair of DiTiDE (Dermatology Indtry Taskforce on Incliveness, Diversity & Equity), a group she co founded in 2020. She has also previoly served on boards of other non profits and biness organizations, including the Canadian Healthcare Licensing Association. Ms. Chypyha earned her Bachelor's Degree from the University of Toronto and a Master's Degree in Biness Administration from Queen's University.
- Charles Olson
-
CharlesV.Olson自2016年12月起担任Stellar的董事，自2014年6月起担任我们的科学顾问委员会成员，并担任薪酬委员会主席。自2017年9月以来，他一直任职于Applied Molecular TransportInc.，担任生物制剂Vice President。2006年以来，他也一直担任Compass Biotechnology LLC的首席生物技术顾问。Olson博士此前于2010年4月至2017年8月在临床阶段生物制药公司NGM Biopharmaceuticals Inc.，专注于生物仿制药的公司Coherus Biosciences Inc.，药物开发公司NexBio Inc.，生物技术公司Cell Genesys，Inc.担任高级和执行管理职位，Biomarin Pharmaceuticals，Inc.，一家为严重和危及生命的罕见疾病开发和商业化疗法的公司，以及OnyxPharmaceuticals，Inc.，一家生物制药公司。研究生毕业后，Olson博士是Kaiser Hospitals的研究科学家，随后分别在Genentech和Bayer担任科学家和高级科学家职位。他持有Westmont College的生物学和化学学士学位、加州大学圣巴巴拉分校（the University of California at Santa Barbara）的化学硕士学位和工商管理硕士学位。在生物化学。Olson博士在生物制药行业拥有丰富的科学、制造运营、工艺开发和高级管理经验。
Charles Olson is a CMC consultant with more than 40 years of biotech experience. Since April 2024 he has also been the Senior Vice President of Technical Operations at NervGen Pharma, responsible for the process development and manufacture of their peptide product in clinical development for nerve regeneration as a result of spinal cord injury. From September 2021 to April 2023 he was Chief Operating Officer at Dendreon Corporation, where he was responsible for the commercial manufacturing of Provenge, a commercial cell based product for prostate cancer, overseeing multiple sites and several hundred employees. From September 2017 to Augt 2021, he was a senior Vice President of Operations at Applied Molecular Transport. From April 2010 to Augt 2017, Dr. Olson held vario leadership roles at Anthera Pharmaceuticals Inc., including Chief Technology Officer. He has also been a Principal Biotechnology Consultant for Compass Biotechnology LLC since 2006. Dr. Olson previoly held senior and executive management positions at NGM Biopharmaceuticals Inc., Coher BioSciences Inc., Nexbio Inc., Cell Genesys, Inc., Biomarin Pharmaceuticals, Inc, and Onyx Pharmaceuticals, Inc. From December 2016 to June 2019, Dr. Olson served on the Board of Edesa Biotech, Inc. (then operating as Stellar Biotechnologies, Inc.), having previoly served on Stellar's scientific advisory board. After graduate school, Dr. Olson was a Research Scientist at Kaiser Hospitals, follod by Scientist and Senior Scientist positions at Genentech and Bayer, respectively. He holds a B.A. in biology and chemistry from stmont College, an M.A. in chemistry from the University of California at Santa Barbara and a D.Sc. in biochemistry. - CharlesV.Olson自2016年12月起担任Stellar的董事，自2014年6月起担任我们的科学顾问委员会成员，并担任薪酬委员会主席。自2017年9月以来，他一直任职于Applied Molecular TransportInc.，担任生物制剂Vice President。2006年以来，他也一直担任Compass Biotechnology LLC的首席生物技术顾问。Olson博士此前于2010年4月至2017年8月在临床阶段生物制药公司NGM Biopharmaceuticals Inc.，专注于生物仿制药的公司Coherus Biosciences Inc.，药物开发公司NexBio Inc.，生物技术公司Cell Genesys，Inc.担任高级和执行管理职位，Biomarin Pharmaceuticals，Inc.，一家为严重和危及生命的罕见疾病开发和商业化疗法的公司，以及OnyxPharmaceuticals，Inc.，一家生物制药公司。研究生毕业后，Olson博士是Kaiser Hospitals的研究科学家，随后分别在Genentech和Bayer担任科学家和高级科学家职位。他持有Westmont College的生物学和化学学士学位、加州大学圣巴巴拉分校（the University of California at Santa Barbara）的化学硕士学位和工商管理硕士学位。在生物化学。Olson博士在生物制药行业拥有丰富的科学、制造运营、工艺开发和高级管理经验。
- Charles Olson is a CMC consultant with more than 40 years of biotech experience. Since April 2024 he has also been the Senior Vice President of Technical Operations at NervGen Pharma, responsible for the process development and manufacture of their peptide product in clinical development for nerve regeneration as a result of spinal cord injury. From September 2021 to April 2023 he was Chief Operating Officer at Dendreon Corporation, where he was responsible for the commercial manufacturing of Provenge, a commercial cell based product for prostate cancer, overseeing multiple sites and several hundred employees. From September 2017 to Augt 2021, he was a senior Vice President of Operations at Applied Molecular Transport. From April 2010 to Augt 2017, Dr. Olson held vario leadership roles at Anthera Pharmaceuticals Inc., including Chief Technology Officer. He has also been a Principal Biotechnology Consultant for Compass Biotechnology LLC since 2006. Dr. Olson previoly held senior and executive management positions at NGM Biopharmaceuticals Inc., Coher BioSciences Inc., Nexbio Inc., Cell Genesys, Inc., Biomarin Pharmaceuticals, Inc, and Onyx Pharmaceuticals, Inc. From December 2016 to June 2019, Dr. Olson served on the Board of Edesa Biotech, Inc. (then operating as Stellar Biotechnologies, Inc.), having previoly served on Stellar's scientific advisory board. After graduate school, Dr. Olson was a Research Scientist at Kaiser Hospitals, follod by Scientist and Senior Scientist positions at Genentech and Bayer, respectively. He holds a B.A. in biology and chemistry from stmont College, an M.A. in chemistry from the University of California at Santa Barbara and a D.Sc. in biochemistry.
- Sean MacDonald
-
Sean MacDonald自2019年6月起担任董事会主席，此前自2017年9月起担任公司主要运营子公司Edesa Biotech Research，Inc.的董事。MacDonald先生目前是Cosmo Pharmaceuticals NV的业务开发主管，这是一家专注于欧洲胃肠病学的制药公司，他自2019年4月以来一直担任该职位，他还担任Corbin Therapeutics的首席执行官，Corbin Therapeutics是一家总部位于蒙特利尔的生物技术公司，专注于治疗神经炎，他自2018年10月起担任该职位。从2012年10月至2018年10月，麦克唐纳先生在Pharmascience Inc.（加拿大最大的制药公司之一）担任过各种运营和执行领导职务，包括业务发展和企业发展的Vice President。他在渥太华大学（University of Ottawa）获得分子生物学学士学位和工商管理硕士学位。
Sean MacDonald has been a member of Board since June 2019, and served as Chairman of the Board from June 2019 until May 2023. He previoly served on the board of principal operating subsidiary, Edesa Biotech Research, from September 2017 to June 2019. In his career, he has led and closed multiple licensing transactions, financings, acquisitions and divestments, and led corporate strategy for several pharmaceutical and biotechnology companies. Since April 2024, Mr. MacDonald has served as the Chief Executive Officer of Domain Therapeutics Inc., a biotechnology company and from January to March 2024, Mr. MacDonald served as their Chief Biness Officer. From April 2022 to February 2024, he served as an advisor to investors and biotechnology companies, including Raya Therapeutic Inc. From Augt 2021 to April 2022, he was the Chief Biness Officer of iOnctura SA, a Swiss clinical stage oncology company. From April 2019 to Augt 2021, he was the Head of Biness Development for Cosmo Pharmaceuticals NV, a European gastroenterology foced pharmaceutical company; and from October 2018 to Augt 2021 he was the chief executive of Corbin Therapeutics, a Montreal based biotech company foced on treating neuroinflammation. Mr. MacDonald held vario operational and executive leadership roles from October 2012 to October 2018 at Pharmascience Inc., one of Canada's largest pharmaceutical companies, including Vice President of Biness Development and Corporate Development. He received his BSc in Molecular Biology and MBA from the University of Ottawa. - Sean MacDonald自2019年6月起担任董事会主席，此前自2017年9月起担任公司主要运营子公司Edesa Biotech Research，Inc.的董事。MacDonald先生目前是Cosmo Pharmaceuticals NV的业务开发主管，这是一家专注于欧洲胃肠病学的制药公司，他自2019年4月以来一直担任该职位，他还担任Corbin Therapeutics的首席执行官，Corbin Therapeutics是一家总部位于蒙特利尔的生物技术公司，专注于治疗神经炎，他自2018年10月起担任该职位。从2012年10月至2018年10月，麦克唐纳先生在Pharmascience Inc.（加拿大最大的制药公司之一）担任过各种运营和执行领导职务，包括业务发展和企业发展的Vice President。他在渥太华大学（University of Ottawa）获得分子生物学学士学位和工商管理硕士学位。
- Sean MacDonald has been a member of Board since June 2019, and served as Chairman of the Board from June 2019 until May 2023. He previoly served on the board of principal operating subsidiary, Edesa Biotech Research, from September 2017 to June 2019. In his career, he has led and closed multiple licensing transactions, financings, acquisitions and divestments, and led corporate strategy for several pharmaceutical and biotechnology companies. Since April 2024, Mr. MacDonald has served as the Chief Executive Officer of Domain Therapeutics Inc., a biotechnology company and from January to March 2024, Mr. MacDonald served as their Chief Biness Officer. From April 2022 to February 2024, he served as an advisor to investors and biotechnology companies, including Raya Therapeutic Inc. From Augt 2021 to April 2022, he was the Chief Biness Officer of iOnctura SA, a Swiss clinical stage oncology company. From April 2019 to Augt 2021, he was the Head of Biness Development for Cosmo Pharmaceuticals NV, a European gastroenterology foced pharmaceutical company; and from October 2018 to Augt 2021 he was the chief executive of Corbin Therapeutics, a Montreal based biotech company foced on treating neuroinflammation. Mr. MacDonald held vario operational and executive leadership roles from October 2012 to October 2018 at Pharmascience Inc., one of Canada's largest pharmaceutical companies, including Vice President of Biness Development and Corporate Development. He received his BSc in Molecular Biology and MBA from the University of Ottawa.
- Carlo Sistilli
-
Carlo Sistilli拥有超过35年的财务经验，并在其职业生涯中担任过多个会计和财务执行职位。他自2019年6月以来一直担任我们的董事会成员，此前曾担任公司的主要运营子公司Edesa Biotech Research，Inc.的董事会观察员（2017年9月以来）。Sistilli先生自2003年3月起担任Arista Homes的首席财务官。在Arista之前，Sistilli先生是一家汽车领域的互联网初创公司的创始人并担任首席财务官和董事会成员，并在将该公司在阿尔伯塔省风险投资交易所上市方面发挥了关键作用。在其职业生涯早期，Sistilli先生是一家主要区域信托公司的财务总监和高级管理团队成员，Sistilli先生帮助将其出售给Manulife Financial。自2021年1月以来，他一直担任Aleafia Health Inc.的董事会和审计委员会成员。除了他的职业生涯，Sistilli先生是Mother of Mercy Center的官员和董事会成员。Sistilli先生持有York University文学学士学位，主修经济学，注册管理会计师指定和特许专业会计师指定。
Carlo Sistilli has more than 35 years of financial experience and has held a variety of executive positions in accounting and finance during his career. He has been a member of Board since June 2019, having previoly served as a board observer of principal operating subsidiary, Edesa Biotech Research, since September 2017. Mr. Sistilli has served as the Chief Financial Officer of Arista Homes since March 2003 to present. Prior to Arista, Mr. Sistilli was a founder and served as CFO and a board member of an Internet start up company in the automotive sector, and played a key role in taking the company public on the Alberta Ventures Exchange. Earlier in his career, Mr. Sistilli was the Controller and a member of the senior management team of a major regional trt company, which Mr. Sistilli helped sell to Manulife Financial. From January 2021 to February 2024, he served on the board of directors and audit committee of Aleafia Health Inc. In addition to his professional career, Mr. Sistilli is an officer and a member of the board of directors of Mother of Mercy Centre. Mr. Sistilli holds a Bachelor of Arts from York University, with a major in economics, Certified Management Accountant Designation and a Chartered Professional Accountant Designation. - Carlo Sistilli拥有超过35年的财务经验，并在其职业生涯中担任过多个会计和财务执行职位。他自2019年6月以来一直担任我们的董事会成员，此前曾担任公司的主要运营子公司Edesa Biotech Research，Inc.的董事会观察员（2017年9月以来）。Sistilli先生自2003年3月起担任Arista Homes的首席财务官。在Arista之前，Sistilli先生是一家汽车领域的互联网初创公司的创始人并担任首席财务官和董事会成员，并在将该公司在阿尔伯塔省风险投资交易所上市方面发挥了关键作用。在其职业生涯早期，Sistilli先生是一家主要区域信托公司的财务总监和高级管理团队成员，Sistilli先生帮助将其出售给Manulife Financial。自2021年1月以来，他一直担任Aleafia Health Inc.的董事会和审计委员会成员。除了他的职业生涯，Sistilli先生是Mother of Mercy Center的官员和董事会成员。Sistilli先生持有York University文学学士学位，主修经济学，注册管理会计师指定和特许专业会计师指定。
- Carlo Sistilli has more than 35 years of financial experience and has held a variety of executive positions in accounting and finance during his career. He has been a member of Board since June 2019, having previoly served as a board observer of principal operating subsidiary, Edesa Biotech Research, since September 2017. Mr. Sistilli has served as the Chief Financial Officer of Arista Homes since March 2003 to present. Prior to Arista, Mr. Sistilli was a founder and served as CFO and a board member of an Internet start up company in the automotive sector, and played a key role in taking the company public on the Alberta Ventures Exchange. Earlier in his career, Mr. Sistilli was the Controller and a member of the senior management team of a major regional trt company, which Mr. Sistilli helped sell to Manulife Financial. From January 2021 to February 2024, he served on the board of directors and audit committee of Aleafia Health Inc. In addition to his professional career, Mr. Sistilli is an officer and a member of the board of directors of Mother of Mercy Centre. Mr. Sistilli holds a Bachelor of Arts from York University, with a major in economics, Certified Management Accountant Designation and a Chartered Professional Accountant Designation.
- Pardeep Nijhawan
-
Pardeep Nijhawan自2019年6月以来一直担任我们的首席执行官，公司秘书和董事会成员，此前曾于2015年1月创立并领导公司的主要运营子公司Edesa Biotech Research，Inc.。Nijhawan博士是一位经验丰富的制药企业家，在金融，营销，企业战略和业务发展的跨职能领导角色方面拥有20年的经验。在Edesa之前，Nijhawan博士于2002年创立了Medical Futures Inc.，并担任其首席执行官。他于2015年将Medical Futures出售给Tribute Pharmaceuticals。Nijhawan博士还于2000年创立了消化健康诊所，并带领其成为加拿大最大的私人内窥镜服务提供商。他于2014年创立Exzell Pharma公司（加拿大专业制药组织，营销和商业化批准的产品）。他继续任职于Exzell Pharma公司和Digistic Health Clinic公司的董事会。2021年1月以来，他曾一直任职Private Debt Partners公司（加拿大另类资产管理公司）的咨询委员会。Nijhawan博士在渥太华大学（University of Ottawa）获得医学博士学位，并在耶鲁大学（Yale University）完成实习，在梅奥诊所（Mayo Clinic）完成内科住院医师和研究金。
Pardeep Nijhawan has served as Chief Executive Officer, Corporate Secretary and a member of Board since June 2019, having previoly founded and led principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross functional leadership roles in finance, marketing, corporate strategy and biness development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada's largest provider of private endoscopy services. He continues to serve on the board of directors of Digestive Health Clinic. From January 2021 until June 2024, he served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic. - Pardeep Nijhawan自2019年6月以来一直担任我们的首席执行官，公司秘书和董事会成员，此前曾于2015年1月创立并领导公司的主要运营子公司Edesa Biotech Research，Inc.。Nijhawan博士是一位经验丰富的制药企业家，在金融，营销，企业战略和业务发展的跨职能领导角色方面拥有20年的经验。在Edesa之前，Nijhawan博士于2002年创立了Medical Futures Inc.，并担任其首席执行官。他于2015年将Medical Futures出售给Tribute Pharmaceuticals。Nijhawan博士还于2000年创立了消化健康诊所，并带领其成为加拿大最大的私人内窥镜服务提供商。他于2014年创立Exzell Pharma公司（加拿大专业制药组织，营销和商业化批准的产品）。他继续任职于Exzell Pharma公司和Digistic Health Clinic公司的董事会。2021年1月以来，他曾一直任职Private Debt Partners公司（加拿大另类资产管理公司）的咨询委员会。Nijhawan博士在渥太华大学（University of Ottawa）获得医学博士学位，并在耶鲁大学（Yale University）完成实习，在梅奥诊所（Mayo Clinic）完成内科住院医师和研究金。
- Pardeep Nijhawan has served as Chief Executive Officer, Corporate Secretary and a member of Board since June 2019, having previoly founded and led principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross functional leadership roles in finance, marketing, corporate strategy and biness development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada's largest provider of private endoscopy services. He continues to serve on the board of directors of Digestive Health Clinic. From January 2021 until June 2024, he served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic.
- Patrick Marshall
-
Patrick Marshall，在筹集资金、构建和推出新产品和服务、制定战略和完成并购以支持私营和上市公司的增长方面拥有超过20年的经验。自2010年以来，他一直担任VRG Capital的董事总经理，此前自2000年以来曾在该公司的多家投资组合公司担任多个执行职务，包括Wheels Group Inc.，一家于2015年被Radiant物流公司收购的北美第三方物流公司，以及Thomas International Ltd.，一家于2018年被Palamon Capital Partners收购的心理测量和能力倾向测试的全球供应商。Marshall先生目前担任Adrem Brands Inc.的总裁兼董事会成员，该公司是一家加拿大私营公司，专注于非处方药和营养补充剂市场，他自2016年1月以来一直担任该职位。在2000年之前，他担任过各种国际企业和非政府组织的筹款、业务发展和战略角色。Marshall先生是Together Project的联合创始人和董事会成员（自2016年起），也是Lakefield College School的受托人（自2012年起）。他在皇后大学获得社会学文学学士学位，在埃克塞特大学获得工商管理硕士学位。
Patrick Marshall has more than 20 years of experience raising capital, building and launching new products and services, developing strategy and completing mergers and acquisitions to support growth in private and public companies. Since 2010 he has been a managing director at VRG Capital, having previoly held vario executive roles in several of the firm's portfolio companies since 2000, including Wheels Group Inc., a North American third party logistics company acquired by Radiant Logistics, Inc. in 2015, and Thomas International Ltd., a global provider of psychometric and aptitude tests acquired by Palamon Capital Partners in 2018. Mr. Marshall is a cofounder and current board member (since 2024) of Crawford Bowman Ltd, a privately held Canadian company foced on over the counter and nutritional supplements markets. He is an advisor to Jouleia Inc, a start up foced on accelerating the transition to low carbon homes. He is a current advisor, past board member (January 2016 – January 2025), and past President (January 2016 December 2023) of Adrem Brands Inc., a privately held Canadian company foced on the over the counter and nutritional supplements markets. Prior to 2000, he held fundraising, biness development and strategy roles for vario international enterprises and non governmental organizations. Mr. Marshall is a cofounder, advisor and former board member of Together Project (2016 2023), a current board member of Faith & the Common Good (since 2025), and a trtee of Lakefield College School (since 2012). He received his Bachelor of Arts in Sociology from Queen's University and Master of Biness Administration from the University of Exeter. - Patrick Marshall，在筹集资金、构建和推出新产品和服务、制定战略和完成并购以支持私营和上市公司的增长方面拥有超过20年的经验。自2010年以来，他一直担任VRG Capital的董事总经理，此前自2000年以来曾在该公司的多家投资组合公司担任多个执行职务，包括Wheels Group Inc.，一家于2015年被Radiant物流公司收购的北美第三方物流公司，以及Thomas International Ltd.，一家于2018年被Palamon Capital Partners收购的心理测量和能力倾向测试的全球供应商。Marshall先生目前担任Adrem Brands Inc.的总裁兼董事会成员，该公司是一家加拿大私营公司，专注于非处方药和营养补充剂市场，他自2016年1月以来一直担任该职位。在2000年之前，他担任过各种国际企业和非政府组织的筹款、业务发展和战略角色。Marshall先生是Together Project的联合创始人和董事会成员（自2016年起），也是Lakefield College School的受托人（自2012年起）。他在皇后大学获得社会学文学学士学位，在埃克塞特大学获得工商管理硕士学位。
- Patrick Marshall has more than 20 years of experience raising capital, building and launching new products and services, developing strategy and completing mergers and acquisitions to support growth in private and public companies. Since 2010 he has been a managing director at VRG Capital, having previoly held vario executive roles in several of the firm's portfolio companies since 2000, including Wheels Group Inc., a North American third party logistics company acquired by Radiant Logistics, Inc. in 2015, and Thomas International Ltd., a global provider of psychometric and aptitude tests acquired by Palamon Capital Partners in 2018. Mr. Marshall is a cofounder and current board member (since 2024) of Crawford Bowman Ltd, a privately held Canadian company foced on over the counter and nutritional supplements markets. He is an advisor to Jouleia Inc, a start up foced on accelerating the transition to low carbon homes. He is a current advisor, past board member (January 2016 – January 2025), and past President (January 2016 December 2023) of Adrem Brands Inc., a privately held Canadian company foced on the over the counter and nutritional supplements markets. Prior to 2000, he held fundraising, biness development and strategy roles for vario international enterprises and non governmental organizations. Mr. Marshall is a cofounder, advisor and former board member of Together Project (2016 2023), a current board member of Faith & the Common Good (since 2025), and a trtee of Lakefield College School (since 2012). He received his Bachelor of Arts in Sociology from Queen's University and Master of Biness Administration from the University of Exeter.
- David Liu
-
David Liu在生物制药工业领域拥有超过10年的投资经验。2023年1月至2024年3月，自2024年12月起，他在Velan Capital Investment Management LP担任高级分析师，该公司是一家位于佐治亚州阿尔法利塔的医疗保健专项投资公司。在担任现职之前，他曾在Altium Capital Management，LP担任生物技术分析师，该投资公司于2019年1月至2022年11月期间专注于医疗保健公司。他在斯坦福大学获得生物科学学士学位，在病态的康奈尔大学医学科学研究生院获得分子生物学博士学位。
David Liu has over 10 years of investment experience within the biopharmaceutical industry. From January 2023 to March 2024, and since December 2024, he has served as a Senior Analyst at Velan Capital Investment Management LP, a healthcare dedicated investment firm based in Alpharetta, Georgia. Prior to his current position, he served as a Biotech Analyst at Altium Capital Management, LP, an investment firm focused on healthcare companies from January 2019 to November 2022. He received his B.S. in Biological Sciences from Stanford University and his Ph.D. in Molecular Biology from ill Cornell Graduate School of Medical Sciences. - David Liu在生物制药工业领域拥有超过10年的投资经验。2023年1月至2024年3月，自2024年12月起，他在Velan Capital Investment Management LP担任高级分析师，该公司是一家位于佐治亚州阿尔法利塔的医疗保健专项投资公司。在担任现职之前，他曾在Altium Capital Management，LP担任生物技术分析师，该投资公司于2019年1月至2022年11月期间专注于医疗保健公司。他在斯坦福大学获得生物科学学士学位，在病态的康奈尔大学医学科学研究生院获得分子生物学博士学位。
- David Liu has over 10 years of investment experience within the biopharmaceutical industry. From January 2023 to March 2024, and since December 2024, he has served as a Senior Analyst at Velan Capital Investment Management LP, a healthcare dedicated investment firm based in Alpharetta, Georgia. Prior to his current position, he served as a Biotech Analyst at Altium Capital Management, LP, an investment firm focused on healthcare companies from January 2019 to November 2022. He received his B.S. in Biological Sciences from Stanford University and his Ph.D. in Molecular Biology from ill Cornell Graduate School of Medical Sciences.
高管简历
中英对照 | 中文 | 英文- Michael Brooks
Michael Brooks于2019年6月被任命为Edesa的总裁，自2015年1月起担任公司主要运营子公司Edesa Biotech Research，Inc.的企业发展和战略Vice President。在加入Edesa之前，Brooks博士于2010年至2015年在Cipher Pharmaceuticals Inc.担任职责递增的职位，最近担任该公司的业务开发总监。加入Cipher之前，Brooks博士是多伦多大学（University of Toronto）的博士后。Brooks博士拥有荣誉学士学位。the University of Toronto微生物学学位和分子遗传学博士学位。Brooks博士在罗特曼管理学院（Rotman School of Management）获得工商管理硕士学位，在那里他是加拿大健康研究所CIHR Science to Business学者。
Michael Brooks was appointed President in June 2019, having served as Vice President of Corporate Development and Strategy for principal operating subsidiary, Edesa Biotech Research, since January 2015. Prior to joining Edesa, Dr. Brooks held positions of increasing responsibility at Cipher Pharmaceuticals Inc from 2010 to 2015 and served most recently as the company's Director of Biness Development. Prior to joining Cipher, Dr. Brooks was a Postdoctoral fellow at the University of Toronto. Dr. Brooks holds a Hons B.Sc. degree in Microbiology and a PhD in Molecular Genetics from the University of Toronto. Dr. Brooks received his MBA degree from the Rotman School of Management where he was a Canadian Institute for Health Research (CIHR) Science to Biness Scholar.- Michael Brooks于2019年6月被任命为Edesa的总裁，自2015年1月起担任公司主要运营子公司Edesa Biotech Research，Inc.的企业发展和战略Vice President。在加入Edesa之前，Brooks博士于2010年至2015年在Cipher Pharmaceuticals Inc.担任职责递增的职位，最近担任该公司的业务开发总监。加入Cipher之前，Brooks博士是多伦多大学（University of Toronto）的博士后。Brooks博士拥有荣誉学士学位。the University of Toronto微生物学学位和分子遗传学博士学位。Brooks博士在罗特曼管理学院（Rotman School of Management）获得工商管理硕士学位，在那里他是加拿大健康研究所CIHR Science to Business学者。
- Michael Brooks was appointed President in June 2019, having served as Vice President of Corporate Development and Strategy for principal operating subsidiary, Edesa Biotech Research, since January 2015. Prior to joining Edesa, Dr. Brooks held positions of increasing responsibility at Cipher Pharmaceuticals Inc from 2010 to 2015 and served most recently as the company's Director of Biness Development. Prior to joining Cipher, Dr. Brooks was a Postdoctoral fellow at the University of Toronto. Dr. Brooks holds a Hons B.Sc. degree in Microbiology and a PhD in Molecular Genetics from the University of Toronto. Dr. Brooks received his MBA degree from the Rotman School of Management where he was a Canadian Institute for Health Research (CIHR) Science to Biness Scholar.
- Pardeep Nijhawan
Pardeep Nijhawan自2019年6月以来一直担任我们的首席执行官，公司秘书和董事会成员，此前曾于2015年1月创立并领导公司的主要运营子公司Edesa Biotech Research，Inc.。Nijhawan博士是一位经验丰富的制药企业家，在金融，营销，企业战略和业务发展的跨职能领导角色方面拥有20年的经验。在Edesa之前，Nijhawan博士于2002年创立了Medical Futures Inc.，并担任其首席执行官。他于2015年将Medical Futures出售给Tribute Pharmaceuticals。Nijhawan博士还于2000年创立了消化健康诊所，并带领其成为加拿大最大的私人内窥镜服务提供商。他于2014年创立Exzell Pharma公司（加拿大专业制药组织，营销和商业化批准的产品）。他继续任职于Exzell Pharma公司和Digistic Health Clinic公司的董事会。2021年1月以来，他曾一直任职Private Debt Partners公司（加拿大另类资产管理公司）的咨询委员会。Nijhawan博士在渥太华大学（University of Ottawa）获得医学博士学位，并在耶鲁大学（Yale University）完成实习，在梅奥诊所（Mayo Clinic）完成内科住院医师和研究金。
Pardeep Nijhawan has served as Chief Executive Officer, Corporate Secretary and a member of Board since June 2019, having previoly founded and led principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross functional leadership roles in finance, marketing, corporate strategy and biness development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada's largest provider of private endoscopy services. He continues to serve on the board of directors of Digestive Health Clinic. From January 2021 until June 2024, he served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic.- Pardeep Nijhawan自2019年6月以来一直担任我们的首席执行官，公司秘书和董事会成员，此前曾于2015年1月创立并领导公司的主要运营子公司Edesa Biotech Research，Inc.。Nijhawan博士是一位经验丰富的制药企业家，在金融，营销，企业战略和业务发展的跨职能领导角色方面拥有20年的经验。在Edesa之前，Nijhawan博士于2002年创立了Medical Futures Inc.，并担任其首席执行官。他于2015年将Medical Futures出售给Tribute Pharmaceuticals。Nijhawan博士还于2000年创立了消化健康诊所，并带领其成为加拿大最大的私人内窥镜服务提供商。他于2014年创立Exzell Pharma公司（加拿大专业制药组织，营销和商业化批准的产品）。他继续任职于Exzell Pharma公司和Digistic Health Clinic公司的董事会。2021年1月以来，他曾一直任职Private Debt Partners公司（加拿大另类资产管理公司）的咨询委员会。Nijhawan博士在渥太华大学（University of Ottawa）获得医学博士学位，并在耶鲁大学（Yale University）完成实习，在梅奥诊所（Mayo Clinic）完成内科住院医师和研究金。
- Pardeep Nijhawan has served as Chief Executive Officer, Corporate Secretary and a member of Board since June 2019, having previoly founded and led principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross functional leadership roles in finance, marketing, corporate strategy and biness development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada's largest provider of private endoscopy services. He continues to serve on the board of directors of Digestive Health Clinic. From January 2021 until June 2024, he served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic.
- Peter Weiler
彼得·伊勒于2025年4月3日被任命为首席财务官，自2025年5月1日起生效。从2018年8月到2025年5月，伊勒先生担任Exzell Pharma，Inc.的总裁，这是一家私人控股的商业阶段制药公司。2017年8月至2018年8月，伊勒先生在Biosyent Inc.（TSX：RX）担任Biness Development副总裁。在此之前，他曾在Cipher制药公司（TSX：CPH）担任多个职务，包括2015年1月至2017年6月担任BINCE Development副总裁、2012年1月至2014年1月担任高级董事、2008年12月至2011年12月担任董事。在加入Cipher之前，他曾在DRI Capital Inc.担任投资分析高级总监，并曾在礼来 Canada Inc.担任市场研究和财务职务。Iler先生拥有安大略大学Ivey Biness学院的Biness Administration硕士学位、安大略大学的Stern University的生物学理学硕士学位以及Wilfrid Laurier大学的理学学士学位（荣誉生物学）和会计学文凭。
Peter Weiler was appointed as Chief Financial Officer on April 3, 2025, effective May 1, 2025. From Augt 2018 to May 2025, Mr. iler served as President of Exzell Pharma, Inc., a privately held, commercial stage pharmaceutical company. From Augt 2017 to Augt 2018, Mr. iler served as Vice President of Biness Development at Biosyent Inc. (TSX: RX). Prior to that, he served in vario roles at Cipher Pharmaceuticals Inc. (TSX: CPH), including Vice President of Biness Development from January 2015 to June 2017, Senior Director from January 2012 to January 2014, and Director from December 2008 to December 2011. Prior to Cipher, he served as Senior Director of Investment Analysis at DRI Capital Inc. and held market research and financial positions at Eli Lilly Canada Inc. Mr. iler holds a Master of Biness Administration degree from the Ivey School of Biness, University of stern Ontario, a Masters of Science in Biology degree from the University of stern Ontario, and a Bachelor of Science (Honors Biology) degree and Diploma in Accounting from Wilfrid Laurier University.- 彼得·伊勒于2025年4月3日被任命为首席财务官，自2025年5月1日起生效。从2018年8月到2025年5月，伊勒先生担任Exzell Pharma，Inc.的总裁，这是一家私人控股的商业阶段制药公司。2017年8月至2018年8月，伊勒先生在Biosyent Inc.（TSX：RX）担任Biness Development副总裁。在此之前，他曾在Cipher制药公司（TSX：CPH）担任多个职务，包括2015年1月至2017年6月担任BINCE Development副总裁、2012年1月至2014年1月担任高级董事、2008年12月至2011年12月担任董事。在加入Cipher之前，他曾在DRI Capital Inc.担任投资分析高级总监，并曾在礼来 Canada Inc.担任市场研究和财务职务。Iler先生拥有安大略大学Ivey Biness学院的Biness Administration硕士学位、安大略大学的Stern University的生物学理学硕士学位以及Wilfrid Laurier大学的理学学士学位（荣誉生物学）和会计学文凭。
- Peter Weiler was appointed as Chief Financial Officer on April 3, 2025, effective May 1, 2025. From Augt 2018 to May 2025, Mr. iler served as President of Exzell Pharma, Inc., a privately held, commercial stage pharmaceutical company. From Augt 2017 to Augt 2018, Mr. iler served as Vice President of Biness Development at Biosyent Inc. (TSX: RX). Prior to that, he served in vario roles at Cipher Pharmaceuticals Inc. (TSX: CPH), including Vice President of Biness Development from January 2015 to June 2017, Senior Director from January 2012 to January 2014, and Director from December 2008 to December 2011. Prior to Cipher, he served as Senior Director of Investment Analysis at DRI Capital Inc. and held market research and financial positions at Eli Lilly Canada Inc. Mr. iler holds a Master of Biness Administration degree from the Ivey School of Biness, University of stern Ontario, a Masters of Science in Biology degree from the University of stern Ontario, and a Bachelor of Science (Honors Biology) degree and Diploma in Accounting from Wilfrid Laurier University.